DEA Releases Cannabis Rescheduling Hearing Preview Ahead of July Session
Federal agency provides glimpse into upcoming testimony as industry awaits critical scheduling decision that could reshape cannabis markets nationwide.
The Drug Enforcement Administration has released preview materials outlining expected testimony for its upcoming cannabis rescheduling hearing, providing the clearest indication yet of arguments federal regulators will consider in determining marijuana's controlled substance classification. The hearing represents the final major procedural step before the DEA renders its decision on moving cannabis from Schedule I to Schedule III under the Controlled Substances Act.
The preview materials signal testimony from medical researchers, industry representatives, and federal health officials who will present evidence on cannabis's therapeutic potential and abuse liability. This testimony will directly influence whether the DEA accepts the Department of Health and Human Services' recommendation to reschedule cannabis, a move that would fundamentally alter the regulatory framework governing the $30 billion U.S. cannabis market.
Rescheduling to Schedule III would eliminate the 280E tax burden that currently prevents cannabis companies from deducting standard business expenses, potentially improving margins by 15-40% across the sector. Multi-state operators like Curaleaf, Green Thumb Industries, and Trulieve stand to benefit most significantly, given their substantial tax liabilities under current federal treatment. The change would also facilitate banking relationships and enable interstate commerce under federal oversight.
The hearing comes as cannabis stocks trade near multi-year lows despite growing state-level legalization momentum. The AdvisorShares Pure US Cannabis ETF has declined over 60% from 2021 peaks, reflecting investor uncertainty around federal policy timelines. Industry analysts view the rescheduling decision as a catalyst that could unlock institutional investment and drive consolidation among fragmented state markets.
The DEA's final determination, expected within 60 days following the hearing, will either validate the Biden administration's cannabis reform agenda or maintain prohibition-era restrictions that have constrained industry growth. Federal rescheduling would create immediate competitive advantages for established operators while potentially opening pathways for pharmaceutical companies to enter cannabis markets through FDA-approved drug development programs.